Cargando…

Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)‐VASc Scores: Findings From the ORBIT‐AF I and II Registries

BACKGROUND: Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA(2)DS(2)VASc=1) (or women with CHA(2)DS(2)VASc=2) a variety of treatment strategies may be considered. However, in clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Larry R., Kim, Sunghee, Fonarow, Gregg C., Freeman, James V., Gersh, Bernard J., Go, Alan S., Hylek, Elaine M., Kowey, Peter R., Mahaffey, Kenneth W., Singer, Daniel, Thomas, Laine, Blanco, Rosalia, Peterson, Eric D., Piccini, Jonathan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201408/ https://www.ncbi.nlm.nih.gov/pubmed/30369317 http://dx.doi.org/10.1161/JAHA.118.008764

Ejemplares similares

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
por: Steinberg, Benjamin A, et al.
Publicado: (2015)

Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
por: Jackson, Larry R., et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry
por: Fudim, Marat, et al.
Publicado: (2018)

Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
por: Washam, Jeffrey B., et al.
Publicado: (2018)

Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF I) Registry
por: O'Brien, Emily C., et al.
Publicado: (2016)

Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF
por: O'Brien, Emily C., et al.
Publicado: (2018)

Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
por: Perino, Alexander C., et al.
Publicado: (2019)

Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry
por: Jackson, Larry R., et al.
Publicado: (2015)

Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
por: Thomas, Kevin L., et al.
Publicado: (2017)

Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
por: Steinberg, Benjamin A., et al.
Publicado: (2018)

Arterial Thromboembolism in Patients With AF and CHA(2)DS(2)-VASc Score 0-2 With and Without Cancer
por: Leader, Avi, et al.
Publicado: (2023)

Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry
por: Fosbol, Emil L., et al.
Publicado: (2013)

CHA(2)DS(2)-VASc: time to settle the score?
por: Kaplan, Rachel M., et al.
Publicado: (2022)

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
por: O'Brien, Emily C., et al.
Publicado: (2015)

CHA(2)DS(2)-VASc and R(2)-CHA(2)DS(2)-VASc scores predict in-hospital and post-discharge outcome in patients with myocardial infarction
por: Węgiel, Michał, et al.
Publicado: (2018)

Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
por: Black‐Maier, Eric, et al.
Publicado: (2017)

CHA(2)DS(2)-Vasc score and CHA(2)DS(2)-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents
por: Zhao, Sheng Gang, et al.
Publicado: (2019)

CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients
por: Gunduz, Ramazan, et al.
Publicado: (2021)

Heart failure: a weak link in CHA(2)DS(2)‐VASc
por: Friberg, Leif, et al.
Publicado: (2018)

CHA(2)DS(2)-VASc Score in Cardio-Oncology: Sharpening the Rules
por: López-Fernández, Teresa
Publicado: (2023)

Predictive value of CHA(2)DS(2)-VASc and CHA(2)DS(2)-VASc-HS scores for failed reperfusion after thrombolytic therapy in patients with ST-segment elevation myocardial infarction
por: Kilic, Salih, et al.
Publicado: (2019)

Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA(2)DS(2)VASC score: CCHA(2)DS(2)VASC score
por: Bungo, Brandon, et al.
Publicado: (2022)

Cheating the CHA(2)DS(2)-VASc Score: Thromboembolism in Apical Hypertrophic Cardiomyopathy
por: Weir, Robin A. P., et al.
Publicado: (2014)

Correlation between CHA(2)DS(2)-VASc Score and Glaucoma Treatment and Prognosis
por: Pikkel, Yoav Y., et al.
Publicado: (2018)

Beyond CHA(2)DS(2)-VASc in atrial fibrillation: the atrium and the risk of stroke
por: Boccanelli, Alessandro
Publicado: (2020)

Escore CHA2DS2-VASc: O Que Mais Podemos Predizer?
por: Maia, Adnaldo da Silveira
Publicado: (2023)

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
por: Steinberg, Benjamin A., et al.
Publicado: (2013)

Value of the CHA(2)DS(2)‐VASc score for predicting outcome in patients with heart failure
por: Shuvy, Mony, et al.
Publicado: (2020)

Coronary Embolism despite CHA₂DS₂-VASc Score of Zero: Should We Reconsider Anticoagulation?
por: Ahmed, Ammar, et al.
Publicado: (2021)

Does CHA2DS2-VASc score predict mortality in chronic kidney disease?
por: Goudis, Christos, et al.
Publicado: (2021)

Stroke and systemic embolism risk in patients with CHA(2)DS(2)‐VASc score of 0
por: Babayiğit, Erdi, et al.
Publicado: (2023)

Heart rate is associated with progression of atrial fibrillation, independent of rhythm
por: Holmqvist, Fredrik, et al.
Publicado: (2015)

Prognostic Impacts of CHADS(2), CHA(2)DS(2)-VASc, and CHA(2)DS(2)-VASc-HS Scores on Clinical Outcomes After Elective Drug-Eluting Stent Placement for De Novo Coronary Stenosis
por: Ukaji, Tomoaki, et al.
Publicado: (2023)

Self-Reported Mobile Health-Based Risk Factor and CHA(2)DS(2)-VASc-Score Assessment in Patients With Atrial Fibrillation: TeleCheck-AF Results
por: Hermans, Astrid N. L., et al.
Publicado: (2022)

High CHA(2)DS(2)-VASc score without atrial fibrillation: ‘NAO yes, NAO no’
por: Perna, Gian Piero
Publicado: (2019)

What should the C (‘congestive heart failure’) represent in the CHA(2)DS(2)‐VASc score?
por: Mulder, Bart A., et al.
Publicado: (2020)

CHA(2)DS(2)‐VASc Score and the Risk of Ventricular Tachyarrhythmic Events and Mortality in MADIT‐CRT
por: Nof, Eyal, et al.
Publicado: (2019)

CHA(2)DS(2)-VASc score stratifies mortality risk in patients with and without atrial fibrillation
por: Harb, Serge C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq42fc38igutv2jq8o146l0s05